BackNascent Biotech Overview

Nascent Biotech Other Liabilities

Latest other liabilities for NBIO: $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Nascent Biotech Other Liabilities History

Loading

Nascent Biotech vs. peers: Other Liabilities Comparison

Loading

Nascent Biotech Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Nascent Biotech (NBIO) FAQ

The latest other liabilities for NBIO is $0 as of September 2024. In the prior-year period, the figure was $0. Investors often review this figure alongside Nascent Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, NBIO's other liabilities moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nascent Biotech's operating scale or balance-sheet position.

A other liabilities figure of $0 for NBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NBIO's other liabilities ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Nascent Biotech's other liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.